Segmental Cardiac Radiation Dose Determines Magnitude of Regional Cardiac Dysfunction.
Breast Neoplasms
/ radiotherapy
Dose-Response Relationship, Radiation
Echocardiography, Three-Dimensional
/ methods
Female
Follow-Up Studies
Heart
/ diagnostic imaging
Humans
Middle Aged
Radiation Injuries
/ complications
Retrospective Studies
Ventricular Dysfunction, Left
/ diagnosis
Ventricular Function, Left
/ physiology
LV dysfunction
breast cancer
cardiotoxicity
global longitudinal strain
radiotherapy
strain echocardiography
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
pubmed:
23
3
2021
medline:
25
2
2023
entrez:
22
3
2021
Statut:
ppublish
Résumé
Background Subclinical left ventricular dysfunction detected by 2-dimensional global longitudinal strain post breast radiotherapy has been described in patients with breast cancer. We hypothesized that left ventricular dysfunction postradiotherapy may be site specific, based on differential segmental radiotherapy dose received. Methods and Results Transthoracic echocardiograms were performed at baseline, 6 weeks, and 12 months postradiotherapy on 61 chemotherapy-naïve women with left-sided breast cancer undergoing tangential breast radiotherapy. Radiation received within basal, mid, and apical regions for the 6 left ventricular walls was quantified from the radiotherapy treatment planning system. Anterior, anteroseptal, and anterolateral walls received the highest radiation doses, while inferolateral and inferior walls received the lowest. There was a progressive increase in the radiation dose received from basal to apical regions. At 6 weeks, the most significant percentage deterioration in strain was seen in the apical region, with greatest reductions in the anterior wall followed by the anteroseptal and anterolateral walls, with a similar pattern persisting at 12 months. There was a within-patient dose-response association between the segment-specific percentage deterioration in strain at 6 weeks and 12 months and the radiation dose received. Conclusions Radiotherapy for left-sided breast cancer causes differential segmental dysfunction, with myocardial segments that receive the highest radiation dose demonstrating greatest strain impairment. Percentage deterioration in strain observed 6 weeks postradiotherapy persisted at 12 months and demonstrated a dose-response relationship with radiotherapy dose received. Radiotherapy-induced subclinical cardiac dysfunction is of importance because it could be additive to chemotherapy-related cardiotoxicity in patients with breast cancer. Long-term outcomes in patients with asymptomatic strain reduction require further investigation.
Identifiants
pubmed: 33749308
doi: 10.1161/JAHA.120.019476
pmc: PMC8174310
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e019476Références
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):182-190
pubmed: 28816145
Phys Med Biol. 2019 Apr 08;64(8):085006
pubmed: 30856618
Am J Med. 1981 Mar;70(3):519-30
pubmed: 6782873
Radiat Oncol. 2019 Nov 14;14(1):204
pubmed: 31727075
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1154-1161
pubmed: 28927756
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):268-76
pubmed: 25968824
J Am Heart Assoc. 2017 May 21;6(5):
pubmed: 28529208
J Thorac Cardiovasc Surg. 2015 Jun;149(6):1643-51.e1-2
pubmed: 25749139
Support Care Cancer. 2016 Jul;24(7):3139-45
pubmed: 26923461
Eur J Echocardiogr. 2006 Mar;7(2):79-108
pubmed: 16458610
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):836-44
pubmed: 26530752
Int J Cardiol. 2017 Sep 15;243:204-208
pubmed: 28587740
Radiother Oncol. 2017 Mar;122(3):416-422
pubmed: 28233564
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Am Heart Assoc. 2021 Apr 6;10(7):e019476
pubmed: 33749308
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiat Res. 2010 Dec;174(6):865-9
pubmed: 21128810
Int J Cardiovasc Imaging. 2017 Apr;33(4):463-472
pubmed: 27873127
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8
pubmed: 20421148
J Am Coll Cardiol. 2015 Jun 16;65(23):2511-22
pubmed: 26065990
Cancer. 2003 Nov 1;98(9):1977-86
pubmed: 14584082
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):10-8
pubmed: 17189062
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1444-51
pubmed: 20605341
Radiother Oncol. 2019 Mar;132:148-154
pubmed: 30414755
Radiother Oncol. 2019 Mar;132:257-265
pubmed: 30446318
Heart Lung Circ. 2019 Sep;28(9):1320-1330
pubmed: 31064715
J Am Coll Cardiol. 2019 Aug 20;74(7):905-927
pubmed: 31416535
Front Oncol. 2018 Apr 04;8:87
pubmed: 29670854
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93
pubmed: 25239940
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Anticancer Res. 2019 Aug;39(8):4227-4236
pubmed: 31366510
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1172-8
pubmed: 23149005